In order to fund their continuous glucose monitoring (CGM) biosensor technology, San Diego, California-based Allez Health, formerly known as Zense-Life, received $60 million in Series A+ funding.
Investors
- Osang Healthcare Co.
- current investors
Use of funds
The money will be used by the firm to support regulatory approval files, increase manufacturing operations, and accelerate expansion towards pivotal trials.
The U.S. Food and Drug Administration and other regulatory bodies have not yet certified or approved the Allez Health sensor, making it an experimental device.
About Allez Health
Allez Health, led by CEO Leif Bowman, offers a CGM biosensor platform with sensor technologies meant to improve user experience and performance. Since its founding, it has achieved a number of significant milestones, such as seven granted patents and more than forty pending patent applications, more than 80 clinical trials involving over 1,500 participants, and a pivotal study involving 120 insulin users. After completing the pivotal study, obtaining significant strategic investment, and signing agreements for specific distribution and manufacturing, Allez Health anticipates accelerating its commercialization process in several international markets, presuming regulatory approvals and ongoing funding availability.
